AI Insight
A multicentre randomised clinical trial in Spain found that temocillin was non-inferior to carbapenems for treating bloodstream infections caused by third-generation cephalosporin-resistant Enterobacterales (3GCR-E). The phase 3 study demonstrated that temocillin is both effective and safe as a targeted treatment for these resistant bacterial infections. This provides clinical evidence supporting temocillin as a viable alternative to carbapenem antibiotics in this specific patient population.
Why it matters
Carbapenems are often considered last-resort antibiotics, and their overuse contributes to the development of extremely resistant bacteria. Having temocillin as an effective alternative could help preserve carbapenems for situations where they are truly needed, supporting better antimicrobial stewardship and helping combat the growing threat of antibiotic resistance.
Understand the Science
In patients with bacteraemia caused by 3GCR-E, temocillin was non-inferior to carbapenems as targeted treatment. These findings support the use of temocillin as an effective and safe alternative to carbapenems in this setting.